CVRx has added an additional approximate $17.7 million to a previous funding round, according to a recently posted SEC filing from the company.
In the equity financing round, which notes its first date of sale as having occurred on May 31, 2016, the Minneapolis-based company reported raising approximately $75.4 million of a total hoped for $93 million.
Money in the offering came from 20 unnamed investors, according to the SEC filing.
CVRx said that the remaining approximate $17.7 million has “already been subscribed by existing investors and the sale of such securities will close when determined by the company’s board of directors,” according to the filing.
Last month, a CVRx-sponsored study involving more than 400 patients suggested that the company’s baroreflex activation therapy showed some promise treating heart failure.